middle.news
Mayne Pharma Surges with 300% EBITDA Growth in 1H FY25
9:23am on Monday 2nd of June, 2025 AEST
•
Pharmaceuticals
Read Story
Mayne Pharma Surges with 300% EBITDA Growth in 1H FY25
9:23am on Monday 2nd of June, 2025 AEST
Key Points
1H FY25 revenues expected between $210 million and $215 million, up 12-14%
Underlying EBITDA forecasted at $30-$32 million, a 275-300% increase from 1H FY24
Growth primarily fueled by Women's Health portfolio and improved Dermatology margins
Cash reserves at $124.9 million as of 31 December 2024, slightly down due to timing of payments
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE